Replies to post #227881 on Biotech Values

[biomaven0]

>>The key then will be who can lock up the remaining large API suppliers via supply exclusivity agreements

But short-term that will be in competition with other generics, so no big bucks to be made. And long-term as other suppliers arrive, also nothing much to be gained. So there's no big win to be had here, except maybe for the first-to-file ANDA holder - anyone know who that was? (If I recall there was a fuss about the initial ANDA filings as the FDA initially maintained only a 3-year exclusivity that was subsequently revised to 5 years). \


I assume folks have seen this:

https://www.markmanadvisors.com/blog/2019/12/3/can-amarins-patents-protect-vascepa-from-generics